Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+900.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ViewRay, Inc. (VRAYQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 900.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +45.8%, EPS growth of +11.9%, a dividend yield of 0.0%. What stands out right now is revenue +45.8%, EPS +11.9%, free cash flow -50.2% with operating margin -104.8% and ROIC -60.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRAYQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRAYQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRAYQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRAYQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$81.0M
-7.8% YoY
FY Net Income
-$76.4M
+36.4% YoY
Free Cash Flow
-$125.9M
-44.1% YoY
Revenue Growth
+45.8%
EPS Growth
+11.9%
Gross Margin
9.8%
Net Margin
-105.2%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 102M | 70M | 57M | 88M | 81M |
| Gross Profit | 10M | 335K | -4M | -5M | 7M |
| Operating Income | -107M | -104M | -106M | -121M | -75M |
| EBITDA | -97M | -100M | -98M | -111M | -65M |
| Net Income | -107M | -110M | -108M | -120M | -76M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 136M | 218M | 157M | 227M | 167M |
| Total Assets | 271M | 322M | 262M | 350M | 295M |
| Total Liabilities | 189M | 152M | 131M | 134M | 128M |
| Shareholder Equity | 82M | 170M | 130M | 216M | 167M |
| Total Debt | 86M | 68M | 68M | 68M | 55M |
| Net Debt | -50M | -150M | -89M | -158M | -112M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
122M
-53.6% YoY
Capital Expenditures
4M
+52.9% YoY
Free Cash Flow
126M
-44.1% YoY
Key ratios
Gross Margin
9.8%
Operating Margin
-104.8%
Net Margin
-105.2%
ROE
-85.3%
Debt / Equity
1.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.